|
1
|
Esteva FJ, Yu D, Hung MC and Hortobagyi
GN: Molecular predictors of response to trastuzumab and lapatinib
in breast cancer. Nat Rev Clin Oncol. 7:98–107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Madrid-Paredes A, Cañadas-Garre M,
Sánchez-Pozo A and Calleja-Hernández MA: Non-HER2 signaling
pathways activated in resistance to anti-HER2 therapy in breast
cancer. Breast Cancer Res Treat. 153:493–505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Madrid-Paredes A, Cañadas-Garre M,
Sánchez-Pozo A and Calleja-Hernández MA: De novo resistance
biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
Pharmacogenomics. 16:1411–1426. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kruser TJ and Wheeler DL: Mechanisms of
resistance to HER family targeting antibodies. Exp Cell Res.
316:1083–1100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fiszman GL and Jasnis MA: Molecular
mechanisms of trastuzumab resistance in HER2 overexpressing breast
cancer. Int J Breast Cancer. 2011:3521822011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Köninki K, Barok M, Tanner M, Staff S,
Pitkänen J, Hemmilä P, Ilvesaro J and Isola J: Multiple molecular
mechanisms underlying trastuzumab and lapatinib resistance in
JIMT-1 breast cancer cells. Cancer Lett. 294:211–219. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nahta R and Esteva FJ: HER2 therapy:
Molecular mechanisms of trastuzumab resistance. Breast Cancer Res.
8:2152006. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jia Y, Zhang Y, Qiao C, Liu G, Zhao Q,
Zhou T, Chen G, Li Y, Feng J, Li Y, et al: IGF-1R and ErbB3/HER3
contribute to enhanced proliferation and carcinogenesis in
trastuzumab-resistant ovarian cancer model. Biochem Biophys Res
Commun. 436:740–745. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang J, Wang Q, Qiao C, Lin Z, Li X, Huang
Y, Zhou T, Li Y, Shen B, Lv M, et al: Potent anti-angiogenesis and
anti-tumor activity of a novel human anti-VEGF antibody, MIL60.
Cell Mol Immunol. 11:285–293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nusrat O, Belotte J, Fletcher NM, Memaj I,
Saed MG, Diamond MP and Saed GM: The role of angiogenesis in the
persistence of chemoresistance in epithelial ovarian cancer. Reprod
Sci. 23:1484–1492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thibault B, Castells M, Delord JP and
Couderc B: Ovarian cancer microenvironment: Implications for cancer
dissemination and chemoresistance acquisition. Cancer Metastasis
Rev. 33:17–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bookman MA, Darcy KM, Clarke-Pearson D,
Boothby RA and Horowitz IR: Evaluation of monoclonal humanized
anti-HER2 antibody, trastuzumab, in patients with recurrent or
refractory ovarian or primary peritoneal carcinoma with
overexpression of HER2: A phase II trial of the Gynecologic
Oncology Group. J Clin Oncol. 21:283–290. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang W, Zhang Y, Lv M, Feng J, Peng H,
Geng J, Lin Z, Zhou T, Li X, Shen B, et al: Anti-IGF-1R monoclonal
antibody inhibits the carcinogenicity activity of acquired
trastuzumab-resistant SKOV3. J Ovarian Res. 7:1032014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ramakrishnan S, Subramanian IV, Yokoyama Y
and Geller M: Angiogenesis in normal and neoplastic ovaries.
Angiogenesis. 8:169–182. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Y, Huang Y, Huang Y, Xia X, Zhang J,
Zhou Y, Tan Y, He S, Qiang F, Li A, et al: JWA suppresses tumor
angiogenesis via Sp1-activated matrix metalloproteinase-2 and its
prognostic significance in human gastric cancer. Carcinogenesis.
35:442–451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hsu TI, Wang MC, Chen SY, Yeh YM, Su WC,
Chang WC and Hung JJ: Sp1 expression regulates lung tumor
progression. Oncogene. 31:3973–3988. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jungert K, Buck A, von Wichert G, Adler G,
König A, Buchholz M, Gress TM and Ellenrieder V: Sp1 is required
for transforming growth factor-beta-induced mesenchymal transition
and migration in pancreatic cancer cells. Cancer Res. 67:1563–1570.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vizcaíno C, Mansilla S and Portugal J: Sp1
transcription factor: A long-standing target in cancer
chemotherapy. Pharmacol Ther. 152:111–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liang X, Li ZL, Jiang LL, Guo QQ, Liu MJ
and Nan KJ: Suppression of lung cancer cell invasion by LKB1 is due
to the downregulation of tissue factor and vascular endothelial
growth factor, partly dependent on SP1. Int J Oncol. 44:1989–1997.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirose T and Horvitz HR: An Sp1
transcription factor coordinates caspase-dependent and -independent
apoptotic pathways. Nature. 500:354–358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao Y, Zhang W, Guo Z, Ma F, Wu Y, Bai Y,
Gong W, Chen Y, Cheng T, Zhi F, et al: Inhibition of the
transcription factor Sp1 suppresses colon cancer stem cell growth
and induces apoptosis in vitro and in nude mouse xenografts. Oncol
Rep. 30:1782–1792. 2013. View Article : Google Scholar : PubMed/NCBI
|
